文献速递系统性红斑狼疮

能否识别系统性红斑狼疮患者中霉酚酸酯获益或受损人群?系统综述

Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2017-02-09

该研究系统检索随机临床试验(RCT)与队列研究,评估预测霉酚酸酯(MMF)在系统性红斑狼疮(SLE)中疗效差异的调节因素及与结局相关的预后因素。共纳入26项研究(7项RCT的13篇报告及13项队列研究),总体证据质量低至极低。结论认为现有证据有限,尚无任何预测因子可推荐用于常规临床实践。

要点

  • 黑人/西班牙裔种族预测狼疮肾炎肾脏反应更佳的证据质量低,且仅来自一项RCT。
  • 队列研究低质量证据提示基线肌酐较高及肾活检膜性特征与狼疮肾炎反应较差相关。
  • 其他调节因素或预后因素的证据质量极低,均不足以支持临床决策。

核心结论

  • 在SLE中,预测MMF反应的因素证据有限,尚无任何因素可推荐用于常规临床实践。
  • 需要基于现有初步证据预设假设、在基线和治疗期间测量预测因素并具备足够把握度的专门研究。

研究设计与样本

  • 系统检索RCT以识别MMF效应的调节因素,并检索队列研究以探索与MMF结局相关的预后因素。
  • 共纳入26项研究,包括7项RCT的13篇报告和13项队列研究。
  • 采用Cochrane偏倚风险工具评估RCT方法学质量,采用QUIPS工具评估队列研究质量。
  • 采用GRADE方法从偏倚风险、不精确性、不一致性、间接性和发表偏倚方面总结证据质量(QoE)。

主要发现

  • 一项RCT提供低QoE证据:黑人/西班牙裔种族/族裔预测狼疮肾炎对MMF的肾脏反应更好。
  • 队列研究提供低QoE证据:较高基线肌酐和肾活检膜性特征与狼疮肾炎反应较差相关。
  • 其他与MMF治疗结局相关的调节因素或预后因素的QoE极低。
  • RCT的QoE受亚组分析为探索性或证据不足影响,两类研究均受高偏倚风险、间接性和不精确性影响。

临床怎么用

  • 现有预测因素证据不足以支持在常规临床实践中用于选择或调整MMF治疗。
  • 临床决策仍应以既有诊疗规范为准,不宜依据本综述所述预测因素常规区分MMF的获益或受损人群。

局限性

  • RCT亚组分析多为探索性或证据不足,影响证据质量。
  • 纳入研究普遍存在高偏倚风险、间接性和不精确性。
  • 整体证据质量低至极低,无法形成可推荐的临床预测工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to summarize the evidence examining factors that predict differential response to mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE). METHODS: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes (response, relapse, or adverse events) were performed. Two reviewers independently assessed the methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation working group approach summarized the quality of evidence (QoE), considering the risk of bias, imprecision, inconsistency, indirectness, and publication bias. RESULTS: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT. There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected by exploratory or insufficient evidence from subgroup analysis and in both study types high risk of bias, indirectness and imprecision also affected QoE. CONCLUSIONS: In SLE, evidence for predictors of response to MMF is limited and none can be recommended for use in routine clinical practice. Specific studies of predictors measured at baseline and during treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufficient power to determine which factors can be employed in clinical decision making.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Mendoza-Pinto C, Pirone C, van der Windt DA, et al. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Semin Arthritis Rheum. 2017. PMID: 28325471. doi:10.1016/j.semarthrit.2017.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。